H. Okamoto

发表

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

R. Jenkins, M. Hibberd, H. Jenkins, 2015, Clinical and Translational Gastroenterology.

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

H. Okamoto, K. Enya, B. Saji, 2018, Advances in Therapy.

Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma

E. Yukawa, S. Higuchi, N. Kondo, 2003 .

Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.

N. Shibata, K. Takada, Weihua Gao, 2002, Journal of pharmaceutical sciences.

A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis

Kiyonori Kobayashi, H. Yamagami, M. Mukae, 2018, Journal of clinical pharmacology.

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

T. Hibi, H. Okamoto, N. Dirks, 2020, Intestinal research.

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Y. Sakurai, A. Nishimura, H. Okamoto, 2015, Alimentary pharmacology & therapeutics.

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

R. Jenkins, M. Hibberd, H. Jenkins, 2015, Alimentary pharmacology & therapeutics.

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

N. Hiramatsu, K. Iwakiri, E. Umegaki, 2017, Therapeutic advances in gastroenterology.

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

Y. Sakurai, A. Nishimura, H. Okamoto, 2016, Clinical Drug Investigation.

Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

Y. Sakurai, A. Nishimura, H. Okamoto, 2016, Advances in Therapy.

Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects

H. Okamoto, R. Xie, Xia Zhao, 2022, European journal of drug metabolism and pharmacokinetics.

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

C. Elmets, R. Dummer, R. Cowan, 2019, Blood.

In‐vitro and in‐vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats

N. Shibata, K. Takada, Weihua Gao, 2002, The Journal of pharmacy and pharmacology.

Pharmacokinetic Interactions between HIV‐1 Protease Inhibitors in Rats: Study on Combinations of Two Kinds of HIV‐1 Protease Inhibitors

N. Shibata, K. Takada, H. Okamoto, 2000, The Journal of pharmacy and pharmacology.

Biopharmaceutical study of the hepatobiliary transport of drugs. VI. Inhibition of active biliary excretion of organic cations by retrograde infusion.

K. Takada, H. Okamoto, S. Muranishi, 1977, Chemical & pharmaceutical bulletin.

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2/D3 Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants

H. Okamoto, R. Whiting, K. Kudou, 2021, Clinical pharmacology in drug development.

Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.

S. Higuchi, H. Okamoto, S. Nakade, 2004, Drug metabolism and pharmacokinetics.